Studies of obicetrapib in people
11 studies gave obicetrapib to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on HbA1cLSMD -0.02%, 95% CI -0.04 to 0.00 down: Lowers the risk of new-onset diabetes6.4% versus 8.5%; adjusted OR 0.69, 95% CI 0.47-1.03 | Review of trials52 weeks | 1,700 people pooledBoth | European journal of preventive cardiology, Oct 24, 2026 |
up: Increases HDL-fraction lipophilic antioxidants down: Decreases oxidized LDL up: Increases HDL2 cholesterol | Trial8 weeks | 12 peopleJapanese participants; n = 12 per group | Scientific reports, Oct 16, 2026 |
down: Decreases LDL-CMD -37.45 down: Decreases non-HDL-CMD -32.04 down: Decreases Apolipoprotein BMD -24.71 | Review of trials | 3,512 people pooledPatient cohorts | Cardiology in review, Jun 29, 2026 |
down: Decreases estimated glomerular filtration rate reduction6.7 % vs. 8.7 % RR 0.77 [0.59, 1.00] no change: Has no effect on blood pressure no change: Has no effect on mortality | Review of trials365 days | 2,880 people pooledBothmean age 64 yearsOlder adults; HeFH or ASCVD | American journal of preventive cardiology, Mar 24, 2026 |
down: Decreases LDL cholesterol-36.3% placebo-adjusted change; 95% CI -42.2% to -30.4% | Randomized trial84 days | 354 peopleBothHeterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy | Nature medicine, Feb 27, 2026 |
down: Decreases LDL cholesterol-33.17% (95% CI, -36.21 to -30.13) down: Decreases non-HDL cholesterol-16.1% (95% CI, -19.1 to -13.1) | Review of trials | 6,025 people pooledOn top of statin therapy | Journal of clinical lipidology, Feb 26, 2026 |
down: Decreases oxidized LDL up: Increases lipophilic antioxidants up: Increases carotenoids | Randomized trial8 weeks | 12 peopleIn Japanese participants | Research Square, Jan 12, 2026 |
down: Decreases LDL-C-33% up: Increases HDL-C+125% down: Decreases p-Tau2171.1% obicetrapib vs. 4.8% with placebo | Randomized trial12 months | 1,727 peopleBothmean 65 yearsOlder adults; atherosclerosis cardiovascular disease | AAIC 2025 abstract, Dec 23, 2025 |
down: Decreases LDL cholesterolMD -27.29 mg/dL; 95% CI -33.65 to -20.93 up: Increases HDL cholesterolMD 70.96 mg/dL; 95% CI 64.71 to 77.20 up: Increases achievement of LDL-C target <55 mg/dLRR 6.42; 95% CI 5.15 to 8.01 | Review of trials | 3,386 people pooledStatin-treated adults | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
down: Decreases total LDL particle number-32.62% vs +7.51% with placebo; between-group difference -40.13% (95% CI -43.33 to -36.93) down: Decreases small LDL particle number-68.02% vs +32.58% with placebo; between-group difference -100.61% (95% CI -110.65 to -90.57) | Randomized trial | 2,024 peopleAlongside maximally tolerated lipid-lowering therapy | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
down: Decreases p-Tau217Adjusted mean increases 2.09% versus 4.94% with placebo | Randomized trial12 months | 1,535 peopleBothMedian age was 67 yearsOlder adults; ASCVD | The journal of prevention of Alzheimer's disease, Oct 17, 2025 |